Compare iShares Global Tech ETF (IXN) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Tech ETF vs Mesoblast Limited — how do they compare? iShares Global Tech ETF trades at $137.71, while Mesoblast Limited trades at $16.38 (market cap $2.17B). The key difference: iShares Global Tech ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| IXN | MESO | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $149.74 | $20.96 |
52-Week Low | $94.04 | $12.88 |
Market Cap | — | $2.17B |
Enterprise Value | — | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IXN trades at $132.95, up 0.25% on the day, with technical indicators showing a bearish trend from moving averages and a neutral stance from oscillators. The stock faces resistance near $134 and support at $132. Recent news highlights its strong tech exposure but cautions that valuations may already reflect high expectations.
The outlook for IXN is mixed, with opportunities in global tech leadership and AI-driven growth, but risks include stretched valuations and concentration in tech. Analyst sentiment leans cautious, emphasizing the need for clearer earnings growth or a more attractive entry point for investment.
MESO trades at $16.63, down 3.98% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $36 million for Ryoncil, showing strong commercial progress, but maintains a net income margin of -144.33% with significant losses. Recent news highlights pivotal Phase 3 trial milestones for chronic low back pain treatment and a $50 million non-dilutive financing draw.
Outlook is mixed: bullish analyst sentiment and clinical advancements offer upside potential, but high cash burn and persistent losses pose substantial risks. Investors should weigh the company's growth trajectory against its financial sustainability and regulatory milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
